Medivation Leads Biotech Launch Expectations
You may also be interested in...
Orexigen Gives The Skinny On Obesity Market During Contrave Update
Orexigen discussed the dynamics of the obesity market as its 9,000-patient cardiovascular outcomes study for the diet pill Contrave gets underway.
Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
Ponatinib received accelerated approval for use in chronic myeloid leukemia and acute lymphoblastic leukemia patients who are resistant or intolerant to prior therapy with tyrosine kinase inhibitors.
Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch
With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.